Phase 2 Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.

CONCLUSION: This combination shows antitumor activity, particularly in patients with MYCN non-amplified tumors. Data on an alisertib oral solution expand the population able to be treated with this agent.
PMID: 30093449 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - August 9, 2018 Category: Cancer & Oncology Authors: Dubois SG, Mosse YP, Fox E, Kudgus RA, Reid JM, McGovern R, Groshen S, Bagatell R, Maris JM, Twist CJ, Goldsmith KC, Granger M, Weiss B, Park JR, Macy ME, Cohn SL, Yanik GA, Wagner LM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Boucher N, Czar Tags: Clin Cancer Res Source Type: research